Increasing experimental evidence, including recently developed animal models support a causal role for uric acid in the development of hypertension. However, it is not clear whether serum uric acid levels are independently associated with the long-term incidence of hypertension. We examined the association between serum uric acid levels and 10-year incidence of hypertension in a population-based cohort study based in Beaver Dam city and township, Wisconsin, US. We studied 2520 hypertension-free individuals (56.3% women, age: 43-84 years, 98% Caucasian) at the baseline examination (1988)(1989)(1990). The main outcome of interest was hypertension (systolic blood pressure (BP) of 140 mm Hg or higher, diastolic BP 90 mm Hg or higher, or combination of self-reported high BP diagnosis and use of antihypertensive medications) incidence over 10 years among baseline normotensive individuals. Nine hundred and fifty-six individuals developed hypertension over a 10-year follow-up period. The relative risk (RR) (95% confidence intervals (CI)) of incident hypertension increased in a dose-dependent manner (P-trendo0.05 in all models) with increasing uric acid quartiles. Multivariable RR (95% CI) comparing the highest quartile of serum uric acid (X390 lmol/l) to the lowest quartile (p260 lmol/l) was 1.65 (1.41-1.93). This association persisted in subgroup analyses by categories of smoking, alcohol intake, body mass index, baseline blood pressure and estimated glomerular filtration rate (GFR). In conclusion, increasing quartiles of serum uric acid was associated with 10-year incidence of hypertension independent of smoking, alcohol intake and baseline kidney function suggesting an independent positive association between serum uric acid levels and hypertension development among community-dwelling older adults.
Introduction
There is increasing experimental laboratory evidence supporting a causal role for uric acid in the development of hypertension. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, previous cross-sectional 1, [11] [12] [13] and longitudinal [14] [15] [16] [17] [18] [19] [20] [21] [22] epidemiologic studies, with the exception of a recent longitudinal analysis from the Framingham Study looking at 4-year hypertension incidence, 22 failed to examine the effect of confounding by important factors such as kidney function, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] alcohol intake 14, 16, 17, 19 and baseline blood pressure. 14 Also, a subsidiary analysis in the report from the Framingham Study examining 12-year incidence of hypertension failed to detect an association between uric acid and hypertension. 22 The independent association between serum uric acid levels and long-term incidence of hypertension in adults is therefore still not clear. Currently, serum uric acid is not considered a risk factor for hypertension by either the American Heart Association 23 or the Joint National Committee (JNC) on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, 24 its measurement removed from routine comprehensive laboratory panel, 25 and asymptomatic hyperuricaemia is considered benign and not requiring treatment. 26 In this context, we examined the relationship between serum uric acid levels and 10-year incidence of hypertension in a populationbased sample from the city and township of Beaver Dam, Wisconsin consisting predominantly of older Americans and Caucasians, after adjusting for several important confounders.
Methods

Study population
The Beaver Dam Eye Study was a populationbased cohort study primarily aimed at studying the distribution and determinants of age-related eye diseases among older Americans in Wisconsin. The methods used to identify and describe the population have appeared in previous reports. 27, 28 In brief, a private census of the population of Beaver Dam, Wisconsin, was performed from September 1987 to May 1988 to identify all residents in the city or township of Beaver Dam who were 43-84 years of age. Of the 5924 eligible individuals (98% Caucasians), 4926 (83.1%) participated in the baseline examination between 1 March 1988 and 14 September 1990. The baseline examination was followed by follow-up cohort examinations every five years in 1993-1995 (n ¼ 3684) and 1998-2000 (n ¼ 2764). The main reason for non-participation at subsequent examinations was mortality. The follow-up rate for non-fatal events was 83% of the total potential person-years of follow-up. Comparisons between participants and non-participants at the time of the baseline and follow-up examinations have appeared elsewhere. 27, 28 In short, those who did not participate in the baseline study were more likely to be older, had fewer years of education, lower income and smoked more pack-years than those who participated in the study. 28 Both the baseline and follow-up examinations followed a similar protocol. Written informed consent was obtained from each subject at each examination. The study was approved by the Human Subjects Committee of the University of Wisconsin School of Medicine and Public Health Institutional Review Board, Madison.
To study the relationship between serum uric acid and incident hypertension, we excluded (not mutually exclusive categories) those with pre-existing hypertension (n ¼ 1576), cancer (n ¼ 221), coronary heart disease (n ¼ 440), stroke (n ¼ 241), end-stage renal disease (n ¼ 57), or gout (n ¼ 106) at baseline, serum creatinine42 mg/dl (n ¼ 35), diuretic users (n ¼ 21), missing serum uric acid levels (n ¼ 341), missing systolic or diastolic blood pressure values (n ¼ 12), missing information on other important covariates (n ¼ 27), including cigarette smoking, glycosylated haemoglobin, total or high density lipoprotein cholesterol levels. There were 2520 hypertensionfree individuals at baseline with relevant covariate information who participated in at least one followup examination; among them 956 developed hypertension during the average 10-year follow-up period.
Exposure ascertainment
The baseline examination and follow-up examinations included measuring weight, height, systolic and diastolic blood pressure by a trained observer, administering standardized questionnaire that collected information regarding participants' demographic characteristics, details regarding cigarette smoking, alcohol intake, physical activity, medical histories and medications taken, including diagnosis of diabetes or hypertension by a physician. Non-fasting blood specimens were obtained for measurement of serum uric acid, plasma glucose, glycosylated haemoglobin, total cholesterol and high-density lipoprotein (HDL) cholesterol and serum creatinine. Serum uric acid was measured using a direct colorimetric method. 29 Average analytical recovery of uric acid in human sera exceeded 99%; within-run and between-run precision studies showed CVs of less than or equal to 1.2 and less than or equal to 2.2%, respectively.
Age was defined as the participants' age at the time of baseline examination. Education was categorized as below high school, high school or beyond high school. Body mass index (BMI) was defined as participants' weight in kilograms divided by the height in metre squared. Persons were defined as having diabetes based on a casual blood sugar of higher than 200 mg/dl (11.1 mmol/l), or if they had a history of diabetes diagnosis by a physician and were treated with insulin, oral hypoglycaemic agents or diet. GFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation, 30 Blood pressure measurement and assessment of hypertension Blood pressure was measured with a random-zero sphygmomanometer according to the Hypertension Detection and Follow-up Programme protocol at each examination. 31 The average of last two out of three total measurements was used for our analysis. Hypertension was defined as systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure 90 mm Hg or higher, or the combination of selfreported high BP diagnosis and use of antihypertensive medications. Normotensive individuals who developed hypertension according to these criteria at either the 5-year or 10-year follow-up examination were defined to have incident hypertension.
Statistical methods
Baseline serum uric acid level was categorized into quartiles (260 or less, 262 to 325, 326 to 389, 390 and above (mmol/l)) for the main analyses. Uric acid was also analysed as a continuous variable (per s.d. (59 mmol/l) increase); uric acid was approximately normally distributed. We used w 2 -test and analysis of variance to compare the relationship of selected baseline characteristics to uric acid quartiles. We used Cox proportional hazards models to determine the relative risk (RR) and 95% confidence interval (CI) of 10-year incident hypertension, controlling simultaneously for potential confounders. We used three nested proportional hazards models in our analysis: the age (years), sex-adjusted model, the multivariable-adjusted model 1, additionally adjusting for education (beyond high school, high school, below high school), BMI (kg/m 2 ), smoking (current, former, never), alcohol consumption (heavy, moderate, never), physical activity (times/week), diabetes status (present, absent), glycosylated haemoglobin (%), total cholesterol: HDL ratio, pulse rate (per min), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg)), and the multivariable adjusted model 2, further adjusting for log-transformed estimated glomerular filtration rate (ml/min/ 1.73 m 2 ). To examine the consistency of the association between uric acid and incident hypertension, we performed analyses within subgroups of selected variables, including categories of smoking (never, former, current), current alcohol intake (absent, present), BMI (25 kg 24 and estimated GFR categories (60 ml/min/ 1.73 m 2 or above, below 60 ml/min/1.73 m 2 ). We examined the joint exposure effect of serum uric acid (quartile 4, quartiles 1-3) and GFR categories (60 ml/min/1.73 m 2 or above, below 60 ml/min/ 1.73 m 2 ) by stratifying the cohort into four corresponding groups. Cross-product interaction terms were used to examine effect modification (a ¼ 0.10) with all variables presented in Table 3 ; only estimated GFR categories showed statistical evidence suggestive of effect modification (P-interaction ¼ 0.06). We also performed the following supplementary analyses. First, we additionally adjusted for white blood cell (WBC) count, a nonspecific marker of inflammation, in multivariable model 2, Table 2 . Second, we repeated the main analyses after excluding the first 5 years of followup. Third, we examined longitudinal changes in systolic and diastolic blood pressure in relation to serum uric acid among study participants not taking antihypertensive medications at follow-up. Fourth, we additionally adjusted for percentage change in BMI during 10 years as a continuous variable in multivariable model 2, Table 2 . SAS version 9.2 was used for all analyses. Table 1 shows the baseline characteristics of the study population according to quartiles of serum uric acid. Compared to individuals in the lowest quartile of serum uric acid, those in the highest quartile were older, had higher BMI, higher 10-year weight gain, were more likely to be current drinkers, more likely to have diabetes, higher glycosylated haemoglobin levels, total cholesterol: HDL ratio, pulse rate, systolic and diastolic blood pressure, and had lower education, less likely to be current smokers, less physically active and lower estimated GFR at the baseline. Table 2 presents the RR of 10-year incident hypertension by quartile of serum uric acid, first, for the whole cohort, and then, separately for men and women. In general, increasing quartiles of serum uric acid was associated with increasing RRs of incident hypertension. Compared to the age, Abbreviations: GFR, glomerular filtration rate; HDL, high-density lipoprotein cholesterol. *P-value estimated by analysis of variance or w sex-adjusted mode l, RRs in the multivariable model 1 were attenuated. Additional adjustment for estimated GFR levels in the multivariable model 2 further attenuated the RRs. The association between serum uric acid and incident hypertension appeared to be stronger for women than for men. Models of trend were statistically significant (P-trend o0.05) for the whole cohort, and separately among women and men. In subsidiary analyses, serum uric acid was analysed as a continuous variable (data not presented in tables); the results were similar and congruent with the analyses presented in Table 2 . The multivariable RR2 (95% CI) of 10-year incident hypertension associated with 1 s.d. (59 mmol/l) increase in uric acid was 1.31 (1.14-1.51).
Results
In Table 3 , we examined the association between serum uric acid (highest vs lowest quartile) and incident hypertension within subgroups of several related variables, including smoking, current alcohol intake, body mass index, JNC 7 blood pressure categories and estimated GFR categories. Overall, serum uric acid was associated with incident hypertension within these subgroups also; the multivariable RRs ranged from 1.2 to 2.4. The association between uric acid and hypertension was stronger among individuals with estimated GFR below 60 ml/min/1.73 m 2 at baseline. We were interested in the effect of low GFR in the relationship between serum uric acid and incident hypertension. Estimated GFR below 60 ml/min/ 1.73 m 2 at baseline was independently associated with incident hypertension in our cohort (Table 4) . Individuals with a joint exposure to both the highest quartile of uric acid and estimated GFR below 60 ml/ min/1.73 m 2 had multivariable RR of 2.4 of incident hypertension compared to individuals with lower uric acid quartiles (quartiles 1-3) and higher GFR levels (P interaction ¼ 0.06).
We performed several sets of supplementary analyses (data not presented in tables). First, to examine whether the observed association between uric acid levels and hypertension were explained by inflammation, we additionally adjusted for WBC count in multivariable model 2, Table 2 ; the RRs were similar and slightly accentuated. Second, we repeated the main analyses (Table 2) after excluding the first 5 years of follow-up; the results were essentially similar. For example, compared to individuals in quartile 1 of serum uric acid (referent), the multivariable RR2 (95% CI) of incident hypertension associated with quartiles 2-4 were, respectively, 1.25 (0.98-1.59), 1.33 (0.99-1.79), 1.84 (1.47-2.30), P-trendo0.01. Third, we examined longitudinal changes in systolic and diastolic blood pressure in relation to serum uric acid among study participants not taking antihypertensive medications at follow-up. After multivariable adjustment, each s.d. (59 mmol/l) increase in serum uric acid was associated with 2.5 mm Hg increase (P ¼ 0.021) in systolic blood pressure and 1.2 mm Hg increase Adjusted for age (years), gender, education (beyond high school, high school, below high school), BMI (kg/m 2 ), smoking (current, former, never), alcohol consumption (heavy, moderate, never), physical activity (times/week), diabetes status (present, absent), glycosylated haemoglobin (%), total cholesterol: HDL ratio, pulse rate (per min), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg). Additionally adjusted for log-transformed estimated glomerular filtration rate (ml/min/1.73 m 2 ). Association between serum uric acid level and long-term incidence of hypertension A Shankar et al (P ¼ 0.04) in diastolic blood pressure between the baseline and 5-year examinations, and 4.2 mm Hg increase (Po0.001) in systolic blood pressure and 2.1 mm Hg increase (P ¼ 0.032) in diastolic blood pressure between the baseline and 10-year examinations. Fourth, to examine if the observed association between uric acid levels and hypertension were explained by interim weight gain, we additionally Adjusted for age (years), gender, education (beyond high school, high school, below high school), BMI (kg/m 2 ), smoking (current, former, never), alcohol consumption (heavy, moderate, never), physical activity (times/week), diabetes status (present, absent), glycosylated haemoglobin (%), total cholesterol: HDL ratio, pulse rate (per min), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), and log-transformed estimated glomerular filtration rate (ml/min/1.73 m 2 ). Adjusted for age (years), gender, education (beyond high school, high school, below high school), BMI (kg/m 2 ), smoking (current, former, never), alcohol consumption (heavy, moderate, never), physical activity (times/week), diabetes status (present, absent), glycosylated haemoglobin (%), total cholesterol: HDL ratio, pulse rate (per min), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg); P-interaction ¼ 0.06. b Additionally adjusted for log-transformed estimated glomerular filtration rate (ml/min/1.73 m 2 ). Association between serum uric acid level and long-term incidence of hypertension A Shankar et al adjusted for percentage change in BMI during 10 years as a continuous variable in multivariable model 2, Table 2 ; the RRs were essentially similar. Compared to individuals in quartile 1 of serum uric acid (referent), the multivariable RR2 (95% CI) of incident hypertension with additional adjustment for percent change in BMI were associated with quartiles 2-4 were, respectively, 1.10 (0.92-1.31), 1.27 (1.08-1.50), 1.63 (1.39-1.91), P-trendo0.01.
Discussion
In a population-based cohort from Beaver Dam, Wisconsin consisting predominantly of older Caucasian individuals, serum uric acid level was found to be associated with the 10-year incidence of hypertension, independent of smoking, alcohol intake, body mass index, diabetes, glomerular filtration rate and other related factors. The RR of hypertension increased in a dose-dependent manner with increasing uric acid quartiles. Results from our study further extend recent evidence from Sundstrom et al. 22 linking serum uric acid and 4-year incident hypertension, by examining longer-term follow-up, and suggesting a critical role for baseline kidney function in this relationship. A joint exposure to the highest quartile of uric acid and estimated GFR below 60 ml/min/1.73 m 2 was found to be associated with RR of 2.4 for incident hypertension compared to individuals with lower uric acid quartiles and higher estimated GFR levels.
Several lines of recent evidence suggest that an association between serum uric acid and hypertension is plausible, including the direct role of uric acid in vascular smooth muscle cell proliferation 6 , endothelial dysfunction and decreased nitric oxide production, [32] [33] [34] proinflammatory features of soluble uric acid, 7, [34] [35] [36] local activation of renin-angiotensin system, 37, 38 and its relation to insulin resistance 39 and components of the metabolic syndrome. 40 Recently developed rat models 2, 3, 8 with experimentally induced mild hyperuricaemia further support a causal association between uric acid levels and hypertension and suggest two distinct phases in hypertension development, 38 including a first phase of salt-resistant hypertension involving uric acid induced renal vasoconstriction and activation of renin-angiotensin system with relatively normal kidney function, 2 and a second phase of more saltsensitive hypertension, involving tubulointerstitial inflammation, renal microvascular disease and arteriosclerosis, that is dependent on kidney function. 8, 41 The development of hypertension in rats was prevented by treatment with either a xanthine oxidase inhibitor (allopurinol) or a uricosuric agent (benziodarone), both of which lowered uric acid levels. 2, 3 In the current study, the magnitude of association between serum uric acid and incident hypertension, its independence from traditional risk factors, including smoking, body mass index and baseline kidney function, evidence of dose-response trend, and the consistency within subgroup analysis by gender and other related variables, suggest that these findings are less likely to be due to chance. Confounding by smoking is a concern in the association between serum uric acid and hypertension, as smoking is associated elevations in uric acid levels 42 and changes in blood pressure. [43] [44] [45] In our study, serum uric acid was associated with incident hypertension even after adjusting for smoking status (Table 2) , and in subgroup analyses, the association was also present among never smokers ( Table 3 ), suggesting that the observed association between serum uric acid and hypertension is not fully explained by smoking. Our findings are consistent with previous cross-sectional 1, [11] [12] [13] and longitudinal studies [14] [15] [16] [17] [18] [19] [20] [21] [22] that reported a positive association between uric acid and hypertension. Furthermore, similar to a recent report from the Framingham Study looking at 4-year incident hypertension, 22 we found the association between uric acid and 10-year incident hypertension to be independent of kidney function, alcohol intake and baseline blood pressure. As urate reabsorption is increased secondary to renal vascular and total peripheral resistance, 9, 46 an observed association between hyperuricaemia and short-term hypertension incidence could be biased by reverse causality, even in prospective studies, due to subclinical hypertension and blood pressure elevations. Our results on the association between uric acid and longer-term hypertension incidence are important in this context. Furthermore, in the current study, a supplementary analysis excluding the first 5 years of follow-up did not materially change the results, suggesting reverse causality not to be a major bias in our findings.
In the current study, a joint exposure to high uric acid levels and low kidney function was associated with higher RR of incident hypertension than their individual effects. These observed findings are consistent with recently proposed unified models of hypertension development, 38 and additionally highlight the critical role of baseline renal function in the development of salt-sensitive hypertension, in vivo. 41 One possibility is that among individuals with already compromised glomerular function, the effect of uric acid-related glomerular arteriosclerosis 8, 41 and subsequent hypertension development 5 is more pronounced. Alternatively, chronic kidney disease in adult populations has been found to be related to insulin resistance. 47 It is possible that the concomitant presence of high uric acid levels and chronic kidney disease is a marker of a more insulin resistant state, 39, 40 which further contributes to their risk of developing hypertension. 48 The main advantages of our study include its stable general population sample base, longitudinal follow-up for up to 10 years, the use of standardized protocols for exposure and outcome assessment, and our ability to examine several important confounAssociation between serum uric acid level and long-term incidence of hypertension A Shankar et al ders in the relationship between serum uric acid and hypertension. Several study limitations need to be considered while interpreting our results. The predominantly Caucasian ethnicity of our study sample limits generalizability of our findings; however, this helped in limiting confounding. We did not have C-reactive protein levels measured in the cohort to examine if the observed association was independent of inflammation. However, in supplementary analyses, adjustment of WBC count, a nonspecific marker of inflammation, did not substantially change the observed findings. Selective survival of our cohort is a possibility. As uric acid levels are related to mortality, 49 selective survival may have resulted in a underestimation of the true association.
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